CoChat

Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma

Open access
Wang, Lindsey, Berger, Nathan A., Xu, Rong · 2021 · JAMA Network Open
Cited by 45

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Recent studies showed a low rate of seroconversion after messenger RNA (mRNA) anti-SARS-CoV-2 vaccination in patients with MM and other hematological malignant neoplasms.3,4 However, the risk and outcomes of SARS-CoV-2 breakthrough infection in vaccinated patients with MM remains unknown. MethodsThis cohort study used the cloud based TriNetX Analytics network platform to access deidentified patient electronic health records (EHRs) from 63 health care organizations in the United States.5 The study population comprised 507 288 patients who fulfilled the following inclusion criteria: had recent medical encounter(s) with health care organizations since December 1, 2020; had documented evidence of full vaccination in the EHRs (Pfizer-BioNTech, Moderna, or Johnson & Johnson vaccine) between December 1, 2020, and October 8, 2021; and had no prior COVID-19 infection.EHR data are deidentified, and this study was exempt from institutional review board approval and informed consent per the US Federal Policy for the Protection of Human Subjects.We tested whether fully vaccinated patients with MM had higher risk for breakthrough infections than individuals without cancer after propensity score matching for demographics, adverse socioeconomic determinants of health, transplant procedures, comorbidities, vaccine types, and medications.Kaplan-Meier analysis was used to estimate probability of breakthrough infections starting 14 days after full vaccination.Comparisons between cohorts were made using Cox proportional hazards model and hazard ratio (HR).We tested whether hospitalization rates differed between patients with MM with breakthrough infections and propensity score-matched patients with MM without breakthrough infections.Statistical tests were either conducted within the TriNetX Analytics Platform or using R statistical software (version 3.6.3)with significance set at P < .05(2-sided).Details of TriNetX, study population, and statistical analysis were described in the eMethods in the Supplement.This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.6 ResultsThe characteristics of the fully vaccinated population with MM and the population of patients without cancer are shown in the Table.Among 1182 vaccinated patients with MM, 33.8% had monoclonal gammopathy of undetermined significance (MGUS), 11.7% were in relapse, 88.7% had never achieved remission, 60.0% had chemotherapy, 50.3% had targeted therapy, 12.1% had radiation therapy, and 26.5% had stem cell transplant; mean (SD) blood lymphocyte count was 2.08 × 10 9 /L (12.2 × 10 9 /L).Among 187 patients with MM with SARS-CoV-2 breakthrough infections, 34.8% had MGUS, 15.5% were in relapse, 86.6% had never achieved remission, 64.2% had +

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2021.37575

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 45

Metadata

Authors
Wang, L., Berger, N. A., & Xu, R.
Venue
JAMA Network Open
Published
2021-11-23
Volume
4
Issue
11
Pages
e2137575
ISSN
2574-3805 (ISSN-L)
OpenAlex
W3217441959
Cited by
45
References
1
FWCI
3.18
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma. https://app.cochat.ai/papers/10.1001/jamanetworkopen.2021.37575
The paper
Wang, L., Berger, N. A., & Xu, R. (2021). Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2021.37575

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.